S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 141 900 KRW 4.49% Market Closed
Market Cap: ₩2.9T

P/OCF

210
Current
254%
More Expensive
vs 3-y average of 59.3

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
210
=
Market Cap
₩3T
/
Operating Cash Flow
₩14B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
210
=
Market Cap
₩3T
/
Operating Cash Flow
₩14B

Valuation Scenarios

ST Pharm Co Ltd is trading above its 3-year average

If P/OCF returns to its 3-Year Average (59.3), the stock would be worth ₩40 058.16 (72% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-96%
Maximum Upside
No Upside Scenarios
Average Downside
74%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 210 ₩141 900
0%
3-Year Average 59.3 ₩40 058.16
-72%
5-Year Average 128.3 ₩86 672.44
-39%
Industry Average 25 ₩16 903.28
-88%
Country Average 9 ₩6 072.49
-96%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
KR
ST Pharm Co Ltd
KOSDAQ:237690
2.9T KRW 210 53.4
US
PerkinElmer Inc
LSE:0KHE
1T USD 1 771.2 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
193.4B USD 24.7 28.8
US
Danaher Corp
NYSE:DHR
130.1B USD 20.3 36
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 36.6 46.1
CH
Lonza Group AG
SIX:LONN
34.9B CHF 29.4 -123.8
CN
WuXi AppTec Co Ltd
SSE:603259
296.1B CNY 17.3 15.6
US
Agilent Technologies Inc
NYSE:A
34.1B USD 24.4 26.4
US
Waters Corp
NYSE:WAT
32.8B USD 50.3 51
US
IQVIA Holdings Inc
NYSE:IQV
29.7B USD 11.2 22
US
Mettler-Toledo International Inc
NYSE:MTD
26.7B USD 27.9 30.7

Market Distribution

Higher than 96% of companies in Korea
Percentile
96th
Based on 1 012 companies
96th percentile
210
Low
0.2 — 4.2
Typical Range
4.2 — 16.6
High
16.6 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 4.2
Median 9
70th Percentile 16.6
Max 2 215 132.4

ST Pharm Co Ltd
Glance View

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

Intrinsic Value
86 835.24 KRW
Overvaluation 39%
Intrinsic Value
Price ₩141 900
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett